Ionis Pharmaceuticals (NASDAQ:IONS) Chairman Stanley T. Crooke sold 13,962 shares of the company’s stock in a transaction that occurred on Tuesday, April 17th. The shares were sold at an average price of $44.40, for a total transaction of $619,912.80. Following the transaction, the chairman now owns 56,714 shares in the company, valued at approximately $2,518,101.60. The sale was disclosed in a filing with the SEC, which is available at this link.
Shares of NASDAQ:IONS traded down $0.17 during midday trading on Thursday, reaching $45.86. The company’s stock had a trading volume of 1,379,128 shares, compared to its average volume of 1,038,015. The firm has a market capitalization of $5,580.91, a P/E ratio of 573.25 and a beta of 2.49. Ionis Pharmaceuticals has a twelve month low of $40.33 and a twelve month high of $65.51. The company has a debt-to-equity ratio of 1.45, a current ratio of 5.20 and a quick ratio of 5.15.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Tuesday, February 27th. The company reported $0.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.10. The firm had revenue of $172.00 million for the quarter, compared to analyst estimates of $126.38 million. Ionis Pharmaceuticals had a negative net margin of 1.18% and a negative return on equity of 1.94%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.33 earnings per share. equities analysts anticipate that Ionis Pharmaceuticals will post -0.13 EPS for the current fiscal year.
A number of brokerages have issued reports on IONS. BidaskClub upgraded shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, April 12th. ValuEngine lowered shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 28th. Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, March 9th. TheStreet lowered shares of Ionis Pharmaceuticals from a “c” rating to a “d+” rating in a research note on Tuesday, February 27th. Finally, BMO Capital Markets upped their price target on shares of Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $52.15.
Large investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC acquired a new stake in shares of Ionis Pharmaceuticals in the third quarter worth $100,000. American International Group Inc. acquired a new stake in shares of Ionis Pharmaceuticals in the fourth quarter worth $147,000. Icon Wealth Partners LLC acquired a new stake in shares of Ionis Pharmaceuticals in the fourth quarter worth $182,000. The Manufacturers Life Insurance Company increased its stake in shares of Ionis Pharmaceuticals by 9.1% in the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock worth $190,000 after acquiring an additional 311 shares during the period. Finally, Hanseatic Management Services Inc. increased its stake in shares of Ionis Pharmaceuticals by 41.1% in the fourth quarter. Hanseatic Management Services Inc. now owns 4,154 shares of the company’s stock worth $209,000 after acquiring an additional 1,210 shares during the period. Hedge funds and other institutional investors own 90.91% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Ionis Pharmaceuticals (IONS) Chairman Sells $619,912.80 in Stock” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://ledgergazette.com/2018/04/19/ionis-pharmaceuticals-ions-chairman-sells-619912-80-in-stock.html.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.